Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4ZLC2
|
|||
| Drug Name |
RXI-109
|
|||
| Synonyms |
A45sd-RxNA
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Phase 2 | [1] | |
| Hypertrophic scars [ICD-11: EE60; ICD-10: L73.0] | Phase 2 | [2] | ||
| Company |
Phio Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CCN2 messenger RNA (CCN2 mRNA) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02246465) A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.